MedTrace Logo

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

NCT06549608 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 685

Last updated 2025-02-24

No results posted yet for this study

Summary

This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.

Conditions

Interventions

DRUG

Mavacamten

As per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-20
Primary Completion
2024-05-06
Completion
2025-04-18
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06549608 on ClinicalTrials.gov